StockDriftsaTYR PHARMA INC · LIFE · DEF 14A · Filed
Seeks Shareholder Approval for Reverse Stock Split to Meet Nasdaq Requirements
LIFE
DEF 14A
Governance
Source: SEC EDGAR, accession 0001339970-26-000061
What did aTYR PHARMA INC announce?
aTyr Pharma is seeking shareholder approval for a reverse stock split with a ratio between 1-for-10 and 1-for-50.
Key details
- Shareholders will vote on a reverse stock split proposal at a Special Meeting on October 16, 2026.
- The proposed reverse stock split ratio can range from 1-for-10 to 1-for-50, at the Board's discretion.
- The primary reason for the split is to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
- The split is also intended to improve stock marketability and liquidity, and effectively increase authorized shares.
Why it matters
This DEF 14A reports a governance matter at aTYR PHARMA INC. The likely share-price reaction reads as negative.
Bearish